
Apremig ODT75 mg
ACI Limited
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist (gepant class) approved for two distinct uses in adults: Established / FDA-Approved Uses Acute treatment of migraine with…
Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist (gepant class) approved for two distinct uses in adults:
Rimegepant is not indicated for the treatment of cluster headache or other headache disorders, and it is not approved for use in children.
Dosing of Rimegepant differs depending on whether it is used for acute or preventive treatment of migraine.
| Indication | Adult Dose | Maximum |
|---|---|---|
| Acute treatment of migraine | 75 mg orally, as a single dose, as needed | Do not exceed 75 mg in 24 hours; safety of more than 18 doses per 30 days has not been established |
| Preventive treatment of episodic migraine | 75 mg orally every other day | One dose every other day; do not increase frequency |
See Administration below for instructions on taking the orally disintegrating tablet.
The most commonly reported adverse effect with Rimegepant is nausea. Other effects reported include:
Most adverse effects are mild to moderate in severity. Patients should seek prompt medical attention for any signs of a serious allergic reaction.
Rimegepant is contraindicated in patients with a known history of hypersensitivity to Rimegepant or any component of the formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.